Talha Badar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7922571/publications.pdf

Version: 2024-02-01

69	663	623734	677142
papers	citations	14 h-index	22 g-index

69	69	69	1049
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasms. Blood Advances, 2022, 6, 528-532.	5.2	27
2	Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen. Leukemia Research Reports, 2022, 17, 100286.	0.4	2
3	Prospect of CAR T-cell therapy in acute myeloid leukemia. Expert Opinion on Investigational Drugs, 2022, 31, 211-220.	4.1	4
4	Realâ€world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts. American Journal of Hematology, 2022, 97, .	4.1	10
5	Realâ€world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts. American Journal of Hematology, 2022, 97, .	4.1	13
6	Outcomes of <scp>TP53</scp>â€mutated <scp>AML</scp> with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American Journal of Hematology, 2022, 97, .	4.1	24
7	Characteristics and prognosis of mutated STAG2 myeloid neoplasms.. Journal of Clinical Oncology, 2022, 40, e19014-e19014.	1.6	0
8	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. Blood Cancer Journal, 2022, 12, .	6.2	1
9	Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.. Journal of Clinical Oncology, 2022, 40, TPS7080-TPS7080.	1.6	0
10	A phase 1 study of CD38-bispecific antibody (XmAb18968) for patients with CD38 expressing relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia.. Journal of Clinical Oncology, 2022, 40, TPS7070-TPS7070.	1.6	2
11	Clinicopathologic characteristics and treatment outcomes of de novo myeloid sarcoma.. Journal of Clinical Oncology, 2022, 40, e19002-e19002.	1.6	1
12	Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms. Current Hematologic Malignancy Reports, 2022, 17, 113-120.	2.3	10
13	Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 683-685.	2.4	7
14	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer, 2021, 127, 82-92.	4.1	15
15	Sequencing of novel agents in relapsed/refractory Bâ€cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer, 2021, 127, 1039-1048.	4.1	16
16	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683.	7.2	45
17	Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?. Expert Opinion on Investigational Drugs, 2021, 30, 665-673.	4.1	2
18	Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplantation, 2021, 56, 1998-2004.	2.4	11

#	Article	IF	Citations
19	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. European Journal of Haematology, 2021, 107, 301-310.	2.2	3
20	Multiâ€center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. American Journal of Hematology, 2021, 96, 1374-1384.	4.1	11
21	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Advances, 2021, 5, 5179-5189.	5.2	21
22	Improved Clinical Outcome of Patients with Myelodysplastic Syndrome (MDS) Progressing after Hypomethylating Agent: In the Era of Novel Therapies. Blood, 2021, 138, 3688-3688.	1.4	0
23	Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies; Significant Impact of Allogeneic Stem Cell Transplantation on Survival. Blood, 2021, 138, 797-797.	1.4	2
24	A Phase 1 Study of XmAb18968, a CD3-CD38 Bispecific Antibody for the Treatment of Patients with Relapsed/Refractory Acute Leukemia and T Cell Lymphoblastic Lymphoma. Blood, 2021, 138, 4401-4401.	1.4	5
25	Epidemiologic and Clinical Analysis of Tumor Mutational Burden (TMB) in Acute Myeloid Leukemia (AML): Exome Sequencing Study of the Mayo Clinic AML Epidemiology Cohort (MCAEC). Blood, 2021, 138, 3437-3437.	1.4	0
26	Trial in Progress: A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Â® Antibody Blinatumomab (Blincyto) and Vincristine Sulfate Liposomal Injection (Marqibo) in Adult Subjects with Relapsed/Refractory Philadelphia Negative CD19+ Acute Lymphoblastic Leukemia. Blood, 2021, 138, 4404-4404.	1.4	0
27	Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study. Blood, 2021, 138, 2158-2158.	1.4	5
28	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. Blood, 2021, 138, 3691-3691.	1.4	1
29	DDX41 Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic DDX41: Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. Blood, 2021, 138, 3693-3693.	1.4	2
30	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 3880-3880.	1.4	4
31	Clinical activity of ibrutinib in classical Hodgkin lymphoma relapsing after allogeneic stem cell transplantation is independent of tumor BTK expression. British Journal of Haematology, 2020, 190, e98-e101.	2.5	9
32	Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances, 2020, 4, 2308-2316.	5.2	29
33	Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Current Treatment Options in Oncology, 2020, 21, 16.	3.0	19
34	Clinical Outcome with Allogeneic Hematopoietic Stem Cell Transplantation after Blinatumomab or Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia: Real World Experience. Biology of Blood and Marrow Transplantation, 2020, 26, S101-S102.	2.0	2
35	Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leukemia and Lymphoma, 2020, 61, 1418-1427.	1.3	16
36	Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 556-560.e2.	0.4	12

#	Article	IF	Citations
37	Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Advances, 2020, 4, 47-54.	5.2	20
38	Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era.. Journal of Clinical Oncology, 2020, 38, e20064-e20064.	1.6	0
39	A Systematic Review of High Dose Chemotherapy with Autologous Transplantation in Secondary CNS Lymphoma. Blood, 2020, 136, 14-14.	1.4	0
40	Comparing the Efficacy of Cyclophosphamide Versus Lenalidomide in Combination with Bortezomib for Newly Diagnosed Multiple Myeloma Treatment: A Systematic Review. Blood, 2020, 136, 42-42.	1.4	0
41	Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Advances, 2019, 3, 1661-1669.	5.2	21
42	Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 210-215.	3.0	2
43	An updated single center experience with plerixafor and granulocyte colonyâ€stimulating factor for stem cell mobilization in light chain amyloidosis. Journal of Clinical Apheresis, 2019, 34, 686-691.	1.3	3
44	Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin. Leukemia and Lymphoma, 2019, 60, 940-946.	1.3	3
45	Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML). Blood, 2019, 134, 5068-5068.	1.4	3
46	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin. Blood, 2019, 134, 1302-1302.	1.4	1
47	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. Blood, 2019, 134, 775-775.	1.4	5
48	Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab. Blood, 2019, 134, 3809-3809.	1.4	3
49	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 753-753.	1.4	9
50	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 3997-3997.	1.4	1
51	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. Blood, 2019, 134, 3483-3483.	1.4	1
52	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. Blood, 2019, 134, 1525-1525.	1.4	10
53	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. Blood, 2019, 134, 5891-5891.	1.4	0
54	Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure. Blood, 2019, 134, 1554-1554.	1.4	0

#	Article	IF	Citations
55	Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplantation, 2018, 53, 1210-1213.	2.4	7
56	A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. Leukemia and Lymphoma, 2018, 59, 515-518.	1.3	4
57	Recent advances in understanding and treating immunoglobulin light chain amyloidosis. F1000Research, 2018, 7, 1348.	1.6	14
58	Androgen receptor expression in patients with triple negative breast cancer treated with neoadjuvant chemotherapy: A single institution experience.. Journal of Clinical Oncology, 2018, 36, e12662-e12662.	1.6	1
59	Morbid obesity is related with adverse outcomes in triple negative breast cancer: A single institution experience.. Journal of Clinical Oncology, 2018, 36, e12663-e12663.	1.6	0
60	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). Blood, 2018, 132, 4153-4153.	1.4	0
61	Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. Blood, 2018, 132, 2918-2918.	1.4	0
62	Predictors of inferior clinical outcome in patients with standardâ€risk multiple myeloma. European Journal of Haematology, 2017, 98, 263-268.	2.2	6
63	Phase I study of evofosfamide, an investigational hypoxiaâ€activated prodrug, in patients with advanced leukemia. American Journal of Hematology, 2016, 91, 800-805.	4.1	31
64	Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement. European Journal of Haematology, 2016, 97, 342-347.	2.2	9
65	Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology, 2015, 90, 1065-1070.	4.1	17
66	Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome. American Journal of Hematology, 2015, 90, 769-773.	4.1	27
67	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leukemia Research, 2015, 39, 950-956.	0.8	69
68	Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research, 2015, 39, 1367-1374.	0.8	48
69	Ibrutinib: a paradigm shift in management of CLL. Expert Review of Hematology, 2014, 7, 705-717.	2.2	17